Microbiological profile of patients with generalized gingivitis undergoing periodontal therapy and administration of Bifidobacterium animalis subsp. lactis HN019: A randomized clinical trial.

Abstract

ObjectiveTo evaluate the adjunctive use of the probiotic Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019) to conventional therapy on clinical and microbiological parameters in patients with generalized gingivitis.MethodsSixty systemically healthy individuals with untreated generalized gingivitis were submitted to periodontal therapy and allocated to receive Placebo (n = 30) or Probiotic (n = 30) lozenges, twice a day for 8 weeks. Bleeding on Marginal Probing (BOMP) was evaluated at baseline, after 2 and 8 weeks. Supra and subgingival biofilm were obtained at baseline and 8 weeks post-therapy for analyses by 16S rRNA gene sequencing. Differences between therapeutic groups were analyzed by non-parametric tests (pResultsThe Placebo and Probiotic groups showed a significant reduction in BOMP at 8 weeks compared to baseline (pConclusionThe adjuvant use of B. lactis HN019 alongside conventional therapy enhanced the reduction in BOMP and promoted greater changes in the microbiological profile of patients with generalized gingivitis.Trial registrationThe study was registered at Brazilian Clinical Trials Registry (ReBEC; protocol number: RBR-59v2yb).